Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study

Standing ovation at ASCO for RASolute 302 Study

Episode metadata supplied by the publisher feed · Published Jun 2, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study

0:00 13:29

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 13 minutes long.

This episode was published on June 2, 2026.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!